10058-F4
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406757

CAS#: 403811-55-2

Description: 10058-F4 is a potent and selective c-Myc inhibitor, which markedly increases valproic acid-induced cell death in Jurkat and CCRF-CEM T-lymphoblastic leukemia cells. 10058-F4 inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. 10058-F4 induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.


Chemical Structure

img
10058-F4
CAS# 403811-55-2

Theoretical Analysis

MedKoo Cat#: 406757
Name: 10058-F4
CAS#: 403811-55-2
Chemical Formula: C12H11NOS2
Exact Mass: 249.0282
Molecular Weight: 249.346
Elemental Analysis: C, 57.80; H, 4.45; N, 5.62; O, 6.42; S, 25.72

Price and Availability

Size Price Availability Quantity
50.0mg USD 150.0 Ready to ship
100.0mg USD 250.0 Ready to ship
200.0mg USD 450.0 Ready to ship
500.0mg USD 900.0 Ready to ship
1.0g USD 1350.0 Ready to ship
2.0g USD 2050.0 Ready to ship
5.0g USD 3550.0 2 weeks
Bulk inquiry

Synonym: 10058-F4; 10058F4; 10058 F4.

IUPAC/Chemical Name: 5-[(4-ethylphenyl)methylene]-2-thioxo-4-thiazolidinone

InChi Key: SVXDHPADAXBMFB-JXMROGBWSA-N

InChi Code: InChI=1S/C12H11NOS2/c1-2-8-3-5-9(6-4-8)7-10-11(14)13-12(15)16-10/h3-7H,2H2,1H3,(H,13,14,15)/b10-7+

SMILES Code: O=C1NC(S/C1=C/C2=CC=C(CC)C=C2)=S

Appearance: Yellow solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: 10058-F4 is a c-Myc inhibitor that specificallly inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression.
In vitro activity: 10058-F4 arrested AML cells at G0/G1 phase, downregulated c-Myc expression and upregulated CDK inhibitors, p21 and p27. Meanwhile, 10058-F4 induced apoptosis through activation of mitochondrial pathway shown by downregulation of Bcl-2, upregulation of Bax, release of cytoplasmic cytochrome C, and cleavage of caspase 3, 7, and 9. Furthermore, 10058-F4 also induced myeloid differentiation, possibly through activation of multiple transcription factors. Similarly, 10058-F4-induced apoptosis and differentiation could also be observed in primary AML cells. Reference: Exp Hematol. 2006 Nov;34(11):1480-9. https://linkinghub.elsevier.com/retrieve/pii/S0301-472X(06)00428-0
In vivo activity: Peak plasma 10058-F4 concentrations of approximately 300 μM are seen at 5 min and declined to below the detection limit at 360 min following a single iv dose. Plasma concentration versus time data are best approximated by a two-compartment, open, linear model. The highest tissue concentrations of 10058-F4 are found in fat, lung, liver, and kidney. Peak tumor concentrations of 10058-F4 are at least tenfold lower than peak plasma concentrations. Eight metabolites of 10058-F4 are identified in plasma, liver, and kidney. The terminal half-life of 10058-F4 is approximately 1 h, and the volume of distribution is >200 ml/kg. No significant inhibition of tumor growth is seen after i.v. treatment of mice with either 20 or 30 mg/kg 10058-F4. Reference: Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18509642/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 49.0 196.51
Ethanol 11.0 44.11

Preparing Stock Solutions

The following data is based on the product molecular weight 249.346 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
In vitro protocol: 1. Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol. 2006 Nov;34(11):1480-9. doi: 10.1016/j.exphem.2006.06.019. PMID: 17046567. 2. Lv M, Wang Y, Wu W, Yang S, Zhu H, Hu B, Chen Y, Shi C, Zhang Y, Mu Q, Ouyang G. C‑Myc inhibitor 10058‑F4 increases the efficacy of dexamethasone on acute lymphoblastic leukaemia cells. Mol Med Rep. 2018 Jul;18(1):421-428. doi: 10.3892/mmr.2018.8935. Epub 2018 Apr 27. PMID: 29749488.
In vivo protocol: 1. Guo J, Parise RA, Joseph E, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25. doi: 10.1007/s00280-008-0774-y. Epub 2008 May 29. PMID: 18509642; PMCID: PMC2752825.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zhang M, Fan HY, Li SC. Inhibition of c-Myc by 10058-F4 induces growth arrest
and chemosensitivity in pancreatic ductal adenocarcinoma. Biomed Pharmacother.
2015 Jul;73:123-8. doi: 10.1016/j.biopha.2015.05.019. Epub 2015 Jun 1. PubMed
PMID: 26211592.

2: Mu Q, Ma Q, Lu S, Zhang T, Yu M, Huang X, Chen J, Jin J. 10058-F4, a c-Myc
inhibitor, markedly increases valproic acid-induced cell death in Jurkat and
CCRF-CEM T-lymphoblastic leukemia cells. Oncol Lett. 2014 Sep;8(3):1355-1359.
Epub 2014 Jun 24. PubMed PMID: 25120723; PubMed Central PMCID: PMC4114592.

3: Guo J, Parise RA, Joseph E, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL.
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max
disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in
mice. Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25. doi:
10.1007/s00280-008-0774-y. Epub 2008 May 29. PubMed PMID: 18509642; PubMed
Central PMCID: PMC2752825.

4: Lin CP, Liu JD, Chow JM, Liu CR, Liu HE. Small-molecule c-Myc inhibitor,
10058-F4, inhibits proliferation, downregulates human telomerase reverse
transcriptase and enhances chemosensitivity in human hepatocellular carcinoma
cells. Anticancer Drugs. 2007 Feb;18(2):161-70. PubMed PMID: 17159602.

5: Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor,
10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of
human acute myeloid leukemia. Exp Hematol. 2006 Nov;34(11):1480-9. PubMed PMID:
17046567.

10058-F4

50.0mg / USD 150.0